Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II

Blood

Volumn 118, Issue 17, 2011, Pages 4750-4758

  Burton, Victoria J ^a   Holmes, Alan M ^a   Ciuclan, Loredana I ^a   Robinson, Alexander ^a   Roger, Jan S ^a   Jarai, Gabor ^a   Pearce, Andrew C ^a   Budd, David C ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; GAMMA INTERFERON; MESSENGER RNA; MYELOPEROXIDASE; SCH 527123; SHORT HAIRPIN RNA; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; EXTRAVASATION; FULTON INDEX; HEART INDEX; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; LEUKOCYTE FUNCTION; LEUKOCYTE MIGRATION; LEUKOCYTE RECRUITMENT; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

EID: 80055086869     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-347393     Document Type: Article

References (21)

1. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44(1):14-30.
2. Tuder RM, Grovers B, Badesch DB. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144(2):275-285. (Pubitemid 24165948)
3. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122(9):920-927.
4. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Cell Mol Biol. 1995;151(5):1620-1631.
5. Itoh T, Nagaya N, Ishibashi-Ueda H, et al. Increased plasma monocyte chemoattractant protein- 1 level in idiopathic pulmonary arterial hypertension. Respirology. 2006;11(2):158-163. (Pubitemid 43356895)
6. Fartoukh M, Emilie D, Le Gall C, et al. Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest. 1998;114(suppl 1):50S-51S. (Pubitemid 28334860)
7. Humbert M, Monti G, Brenot F. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Crit Care Med. 1995;151(5):1628-1631.
8. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol. 1994;11(6):664-675.
9. Ikeda Y, Yonemitsu Y, Kataoka C, et al. Antimonocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol. 2002; 283(5):H2021-H2028. (Pubitemid 35217037)
10. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S32-S42.
11. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105(14):1672-1678. (Pubitemid 34298611)
12. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159-165. (Pubitemid 38114133)
13. Burton VJ, Ciuclan LI, Holmes AM, Rodman DM, Walker C, Budd DC. Bone morphogenetic protein receptor-II regulates pulmonary artery endothelial cell barrier function. Blood. 2011;6:117(1):333-341.
14. Liu D, Wang J, Kinzel B, et al. Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood. 2007;110(5): 1502-1510. (Pubitemid 47443965)
15. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol. 1997;15: 675-705. (Pubitemid 27169296)
16. Reutershan J, Morris MA, Burcin TL, et al. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. J Clin Invest. 2006; 116(3):695-702. (Pubitemid 43326878)
17. Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009;121(1):55-68.
18. Chapman RW, Minnicozzi M, Celly CS, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther. 2007;322(2):486-493. (Pubitemid 47105794)
19. Thatcher TH, McHugh NA, Egan RW, et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol. 2005;289(2):L322-L328. (Pubitemid 41008916)
20. Hong KH, Lee YJ, Lee E, et al. Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 2008;118(7):722-730.
21. Sue RD, Belperio JA, Burdick MD, et al. CXCR2 is critical to hyperoxia-induced lung injury. J Immunol. 2004;172(6):3860-3868. (Pubitemid 38337973)